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| INTRODUC TI ON
Prostate cancer is one of the most commonly diagnosed malignancies among men and is the fourth most common cancer among men worldwide. 1 Mortality occurs due to metastasis of PCa that is present either at the time of diagnosis or after failure of primary treatment. Metastatic disease indicates poor prognosis in men with PCa, and correlates with significant mortality. 2 Most of the metastatic PCa cases eventually develop resistance to primary androgen deprivation therapy, a condition known as metastatic castration-resistant prostate cancer. 2 However, little is known about the molecular mechanisms involved in the metastasis of PCa cells, which ultimately limits the development of effective therapies that aimed to prevent the spread of PCa cells. Therefore, identification of novel genes that are functionally involved in PCa development and progression or new markers that have the capability to predict or classify metastatic disease in the early stage could help to investigate potential diagnostic and therapeutic targets.
In recent years, rapid development has been observed in next-generation sequencing technology, which indicates that genetic and epigenetic changes are the primary drivers of PCa. 3 For human PCa, epigenetic alterations are not only involved in the initial tumorigenesis process, but also in the continuous regulation of subsequent progression of the malignancy. 4, 5 An indepth understanding regarding the epigenetic changes in PCa provides new opportunities for the discovery of biomarkers for screening, diagnosis, and risk stratification of PCa. 6 Methylation of the promoter DNA leads to the silencing of the genes involved, and plays crucial roles in tumorigenesis. In addition, abnormal DNA methylation occurs even earlier than genetic events, such as loss of heterozygosity and microsatellite instability, 7, 8 and much earlier than the changes of protein biomarkers. This in turn produced DNA methylation abnormality as a biomarker that is more sensitive and valuable than genetic aberrations and protein biomarkers.
Members of the UNC5 family, including four homologues (UNC5A-D), were originally identified as netrin receptors and are considered to participate in the regulation of cell migration and morphogenesis during development. 9 The expression of UNC5 homologues was downregulated in many human malignancies due to genetic and epigenetic alterations. 10 UNC5 receptors have been reported to function as "dependence receptors" owing to their dependence on the availability of netrin-1 for cell survival. 10, 11 Although UNC5H receptors share high homology with each other, their functions are not exactly the same. 10, 12, 13 
| Cell lines, Abs, and drug treatments
All PCa cell lines used in this study were obtained from the Cell Bank of the Chinese Academy of Medical Sciences (Beijing, China), and maintained in RPMI-1640 supplemented with 10% FBS (Gibco-BRL, Gaithersburg, MD, USA) and 1% penicillin/streptomycin. Antibodies specific to UNC5D, β-actin, and DAPK1 were purchased from SigmaAldrich (St. Louis, MO, USA). Anti-phospho-DAPK1 Ab (Ser-308) was purchased from Cell Signaling Technology (Beverly, MA, USA).
For demethylation assays, cell lines were treated with 10 mmol/L 5-aza-2-deoxycytidine (Sigma-Aldrich) for 3 days with exchange of reagents and medium every 24 hours. For experiments using the
Sigma-Aldrich), cells were plated in 24-well plates, pretreated for 60 minutes with 25 μmol/L DAPK inhibitor, and then maintained with DAPK1 inhibitor at the concentration of 1 μmol/L (in media with 0.1% DMSO). Media alone with 0.1% DMSO was used as vehicle control.
| Methylation analysis of UNC5D
Genomic DNA (500 ng) was bisulfite converted following EZ DNAMethylation Gold kit instructions (Zymo Research, Irvine, CA, USA).
Methylation-specific PCR and bisulfate genomic sequencing analysis were carried out as described previously. undertaken as described previously. 21 Sequence information for the primers and probes used is listed in Table S1 .
| Immunohistochemistry and scoring
Tissue sections were incubated with anti-UNC5D Ab (Sigma-Aldrich) at 1:200 dilution overnight at 4°C. The sections were then washed and subsequently incubated with a universal secondary Ab for 1 hour at room temperature. The scoring method that combined intensity and percentage of positivity was previously described, 22 and extent and intensity measures for each core were combined as weak (score 1), moderate (score 2), and strong (score 3).
| Transfection, infection, and western blot analysis
Adenoviruses expressing UNC5D, UNC5D-∆DD (UNC5D without the death domain 17 ), or MOCK were packaged by the Vector Gene
Technology Company (Beijing, China). Prostate cancer cell lines were infected with 20 MOI of the adenoviral vector. JetPRIME transfection reagent (Polyplus-transfection, Illkirch, France) was used for all transfections in this study. All western blots were detected by electrochemiluminescence (GE Healthcare Life Sciences, Uppsala, Sweden). Beta-actin (Sigma-Aldrich) was used as the internal control.
| Knockdown of UNC5D
Two UNC5D-specific Stealth siRNA, targeting the noncoding region of UNC5D and a negative control siRNA, were purchased from Invitrogen (Carlsbad, CA, USA). Transfection was carried out using the jetPRIME transfection reagent (Polyplus-transfection) according to the manufacturer's instructions. After transfection for 72 hours, the cells were harvested for further analysis. Sequence information for the siRNA used is listed in Table S1 .
| Immunoprecipitation
The IP was carried out as described previously. 23 
| Wound healing assay
Cell motility was determined by measuring the movement of cells to close an artificial wound. Cells were seeded in 24-well plates at 80%
confluence. Cells were wounded with a 200-μL pipette tip, washed with PBS, and incubated with medium containing 1% FBS. The distance traveled by cells was monitored by phase-contrast microscopy (Olympus, Tokyo, Japan) at indicated time points.
| Cell migration and invasion assay
For cell migration assay, PCa cells were seeded into Transwell inserts 
| In vivo metastasis assay
For lung metastasis assays, the androgen-independent DU145 cells were infected with adenoviruses expressing UNC5D or MOCK. Twentyfour hours after infection, the cells were trypsinized and washed with PBS. A total of one million cells in 100 μL were injected into the tail vein of nude mice. At 6 weeks after injection, the animals were killed and lungs were harvested and fixed in 10% formaldehyde/PBS before being assessed for evidence of metastases by H&E staining. In in vivo experiments, the female Nu/Nu nude mice at age of 4 weeks were maintained under specific pathogen-free conditions. All animal protocols were in accordance with guidelines for animal care and were approved by the Animal Ethics Committee of Tianjin Medical University.
| Statistical analysis
Quantitative data were expressed as data plots or mean ± SD. All statistical tests were undertaken using SPSS (version 13.0; SPSS, Chicago, IL, USA). Value of P < .05 was taken as statistical significance.
| RE SULTS

| Downregulated expression of UNC5D in primary and metastatic PCa
First, a meta-analysis of UNC5D expression was carried out through the publicly available microarray datasets GEO (https://www.ncbi. strong, medium, and weak expression levels were calculated separately. As shown in Figure 1E , the UNC5D protein was significantly downregulated in primary PCa tissues compared to noncancerous tissues, and least expression was observed in the metastatic tumors.
| Promoter hypermethylation of UNC5D in cell lines and primary PCa
The mechanism for the downregulated expression of UNC5D in low-expression group (n = 29). Ten of 31 in the UNC5D high-expression group, and 19 of 29 in the UNC5D low-expression group were positively methylated. UNC5D expression was significantly associated with promoter hypermethylation ( Figure 2E ; P = .0009, Fisher's exact test).
F I G U R E 2 Promoter methylation contributes to the suppressed expression of UNC5D in cell lines and primary prostate cancer (PCa
| Positive correlation between methylation level of UNC5D and the metastasis of PCa
MethyLight assay was used to analyze the methylation in an accurate and quantitative manner. This detection system containing 9 
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CpG sites (3 in the forward primer, 2 in the reverse primer, and 4 in the TaqMan probe; Table S1 ), and the oligonucleotides with all these sites methylated will be annealed and amplified. All the metastatic tumors, primary tumors, and paired noncancerous tissues were detected. As shown in Figure 3A , the methylation levels in the promoter of UNC5D were the highest in metastatic tumors, followed by primary tumors, and the lowest in adjacent nontumor tissues.
In addition, a significant inverse correlation between UNC5D expression and promoter methylation was observed for PCa samples ( Figure 3B , r = −0.448, P < .0001). Taken together, these data indicated that the promoter methylation was the major cause of UNC5D downregulation in PCa.
| Restoration of UNC5D expression suppresses the migration and invasion of PCa cell lines
Frequent downregulation of UNC5D in PCa tissues, especially meta- 
| Silencing of UNC5D enhances the metastatic ability of PCa cells
To further confirm the inhibitory effects of UNC5D on PCa cell metastasis, UNC5D expression was knocked down by siRNA in PC-3 cells, showing endogenous expression of UNC5D to a certain extent. Figure 5C,D) . This experiment further confirmed the metastatic-suppressive effect of UNC5D in PCa.
| DAPK1 is essential for the metastasis suppressor function of UNC5D
UNC5D shares high homology with other members that were discovered previously, in both sequence and structure.
10 UNC5A, UNC5C, and especially UNC5B are capable of binding with the serine/threonine kinase, DAPK1, 24 which is a key intracellular kinase with both apoptosis-inducing 25, 26 and motility-inhibitory functions. 27, 28 The apoptosis-inducing biological effect of UNC5B is achieved by recruiting and activating DAPK1. 24, 26 This subsequently led us to speculate whether the antimetastatic effect of UNC5D in PCa is mediated by DAPK1.
The expression of DAPK1 in PCa tissues and cell lines was analyzed. Three publicly available microarray datasets (2 from GEO, both from GSE6919; 1 from Oncomine, Taylor Prostate) were selected to undertake the meta-analysis of DAPK1 expression.
Although usually reported as a tumor suppressor gene, expression We then investigated whether UNC5D could recruit and activate DAPK1. The co-IP assays were carried out in DU145 cells infected with adenoviruses expressing UNC5D. As shown in Figure 6A , UNC5D and DAPK1 were IP with each other. Decreased levels of phosphorylation at Ser-308 showed the active state of DAPK1. 29, 30 Western blot analysis indicated that DAPK1 was obviously activated in DU145-UNC5D cells more than DU145-MOCK cells ( Figure 6B ).
As reported, the death domains of UNC5 family members remained crucial for their biological function in tumor cells. 10 Therefore, DU145 cells were also infected with adenoviruses expressing UNC5D-∆DD.
As shown in Figure 6B Taken together, these data illustrated that DAPK1 could interact with UNC5D and might mediate its inhibitory function.
| D ISCUSS I ON
Epigenetic changes are common features of PCa, and play key roles in the initiation and progression of cancer. 5 As for UNC5D, hypermethylation alterations at the promoter region are one of the main causes for its repression in a variety of tumors, [15] [16] [17] [18] and are the same F I G U R E 6 DAPK1 is essential for the metastasis suppressor function of UNC5D. A, Interaction between UNC5D and DAPK1. DU145 cells were infected with UNC5D-expressing adenoviruses. Cell lysates were immunoprecipitated (IP) with anti-UNC5D and IgG control (upper) or DAPK1 and IgG control (lower). Western blot analysis was undertaken to detect DAPK1 and UNC5D, respectively. B, DU145 cells were infected with MOCK, UNC5D-∆DD-or UNC5D-expressing adenoviruses. Western blot analysis was used to detect the expression of UNC5D and UNC5D-ΔDD, as well as the activation of DAPK1. The DAPK1 protein and actin were used as internal controls. C,D, The essential role of the death domain for the function of UNC5D. DU145 cells were infected with MOCK, UNC5D-∆DD-or UNC5D-expressing adenoviruses. Wound healing (C) and Transwell migration (D) assays were used to compare cell motilities of these cells. E,F, DU145 cells were infected with MOCK or UNC5D-expressing adenoviruses, then the inhibitor of DAPK1 or the vehicle control (media with 0.1% DMSO) were added in the wound healing assay (E) and Transwell migration assay (F) to compare cell motilities. Results are expressed as mean ± SD of 3 independent experiments. *P < .05; **P < .01; ***P < .001
in PCa cells according to our study. However, there are seldom reports on the methylation status of UNC5D in metastatic tumors. Our data indicated that the methylation changes exist not only in primary PCa, but also in metastatic tumors, and in a more reinforced manner, accounting for further downregulation of UNC5D in the metastatic tumors. Large-scale cancer genome sequencing studies in the genome of invasive PCa showed catastrophic hypermethylation alterations, involving hundreds to thousands of CpG islands, and the majority of these were highly methylated across the metastasis process within the individuals. 31 Thus, cancer metastasis could be driven by cumulative expression disorders, where hypermethylation occurs in genes that are key components in the metastatic pathways.
In this study, we tried to determine whether UNC5D might act as one such key component.
Recently, it has been reported that UNC5 family receptors act as dependent receptors for netrin-1, and these receptors induce apoptosis when not engaged with their ligand. 10 However, it is not always the case. Except from apoptosis induction, the UNC5 homolog family also plays other important roles that are independent of netrin-1. UNC5B could interact with FLRT3 and Rnd1 to modulate cell adhesion in Xenopus embryos, 12 and the UNC5D/ FLRT2 complex regulates the radial migration of cortical cells. 13 These findings indicated that whether the dependent receptors induce apoptosis depends on various factors both intracellularly and extracellularly. 32 For tumor cells, the factors that influenced apoptosis are considered to be more complicated. It is well known that many malignant cells gain resistance to apoptosis to evade chemotherapy. 33, 34 Typical examples include renal cell carcinoma cells 35 and advanced PCa cells. 36 Both UNC5C and UNC5D have no apoptosis-inducing effects on renal carcinoma cells, 17,37 whereas UNC5D exerted tumor suppressive effects mainly by cell cycle arrest in renal carcinoma cells. 17 In this study, we showed that UNC5D has the capability to suppress the metastatic ability of PCa cells. Moreover, the suppressive function of UNC5D was dependent on DAPK1 in the downstream. DAPK1 is a key intracellular kinase that has both apoptosis-inducing and motility-inhibitory functions. [25] [26] [27] [28] In apoptosis-sensitive cells, DAPK1 participates in a wide range of apoptotic signals. 27, 28 In tumor cells that are resistant to DAPK-induced apoptosis, DAPK has a motility-inhibitory effect and functions as a determining factor in tumor cell inva- could be a potential diagnostic biomarker and therapeutic target for metastatic PCa.
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